Cargando…
Lifetime Cannabis Use Is Not Associated With Negative Beliefs About Medication in Patients With First Treatment Psychosis
OBJECTIVE: Cannabis use is common among patients with psychosis, and along with negative beliefs about medication, it has been found to predict poor adherence to antipsychotic drug treatment. Such lack of adherence to antipsychotic drug treatment increases the risk of poor clinical outcomes and rela...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9001842/ https://www.ncbi.nlm.nih.gov/pubmed/35422717 http://dx.doi.org/10.3389/fpsyt.2022.824051 |
_version_ | 1784685759090917376 |
---|---|
author | Gjerde, Priyanthi B. Steen, Synne W. Vedal, Trude S. J. Steen, Nils Eiel Reponen, Elina J. Andreassen, Ole A. Steen, Vidar M. Melle, Ingrid |
author_facet | Gjerde, Priyanthi B. Steen, Synne W. Vedal, Trude S. J. Steen, Nils Eiel Reponen, Elina J. Andreassen, Ole A. Steen, Vidar M. Melle, Ingrid |
author_sort | Gjerde, Priyanthi B. |
collection | PubMed |
description | OBJECTIVE: Cannabis use is common among patients with psychosis, and along with negative beliefs about medication, it has been found to predict poor adherence to antipsychotic drug treatment. Such lack of adherence to antipsychotic drug treatment increases the risk of poor clinical outcomes and relapse in patients with first treatment for psychosis (FTP). However, to date, it is unclear whether cannabis use may be related to negative perceptions about antipsychotic drug treatment. METHODS: A cross-sectional sample of 265 FTP patients with schizophrenia spectrum disorder underwent extensive clinical assessments. Three measures of cannabis use were obtained: lifetime, current and meeting diagnostic criteria for abuse or addiction. For the primary analyses we focused on lifetime cannabis use. The Beliefs about Medication Questionnaire (BMQ) was employed to assess the patients' specific concerns and perceptions of antipsychotic medications, as well as general beliefs about pharmacotherapy. The relationship between lifetime cannabis use and BMQ scores was investigated with general linear model (GLM) analyses, controlling for age and sex. RESULTS: Patients with lifetime use of cannabis ≥10 times were more likely to be male, younger at the age of onset of psychosis and with higher levels of alcohol use and daily tobacco smoking, as compared to the non-users (p < 0.05). Neither lifetime use of cannabis, current use nor a cannabis abuse diagnosis was associated with negative beliefs about medicines as measured by the BMQ questionnaire. CONCLUSION: Use of cannabis is not linked to negative perceptions about antipsychotic medicines in patients with FTP. Other reasons for poor compliance to antipsychotic drug treatment in cannabis users need to be further investigated. |
format | Online Article Text |
id | pubmed-9001842 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90018422022-04-13 Lifetime Cannabis Use Is Not Associated With Negative Beliefs About Medication in Patients With First Treatment Psychosis Gjerde, Priyanthi B. Steen, Synne W. Vedal, Trude S. J. Steen, Nils Eiel Reponen, Elina J. Andreassen, Ole A. Steen, Vidar M. Melle, Ingrid Front Psychiatry Psychiatry OBJECTIVE: Cannabis use is common among patients with psychosis, and along with negative beliefs about medication, it has been found to predict poor adherence to antipsychotic drug treatment. Such lack of adherence to antipsychotic drug treatment increases the risk of poor clinical outcomes and relapse in patients with first treatment for psychosis (FTP). However, to date, it is unclear whether cannabis use may be related to negative perceptions about antipsychotic drug treatment. METHODS: A cross-sectional sample of 265 FTP patients with schizophrenia spectrum disorder underwent extensive clinical assessments. Three measures of cannabis use were obtained: lifetime, current and meeting diagnostic criteria for abuse or addiction. For the primary analyses we focused on lifetime cannabis use. The Beliefs about Medication Questionnaire (BMQ) was employed to assess the patients' specific concerns and perceptions of antipsychotic medications, as well as general beliefs about pharmacotherapy. The relationship between lifetime cannabis use and BMQ scores was investigated with general linear model (GLM) analyses, controlling for age and sex. RESULTS: Patients with lifetime use of cannabis ≥10 times were more likely to be male, younger at the age of onset of psychosis and with higher levels of alcohol use and daily tobacco smoking, as compared to the non-users (p < 0.05). Neither lifetime use of cannabis, current use nor a cannabis abuse diagnosis was associated with negative beliefs about medicines as measured by the BMQ questionnaire. CONCLUSION: Use of cannabis is not linked to negative perceptions about antipsychotic medicines in patients with FTP. Other reasons for poor compliance to antipsychotic drug treatment in cannabis users need to be further investigated. Frontiers Media S.A. 2022-03-29 /pmc/articles/PMC9001842/ /pubmed/35422717 http://dx.doi.org/10.3389/fpsyt.2022.824051 Text en Copyright © 2022 Gjerde, Steen, Vedal, Steen, Reponen, Andreassen, Steen and Melle. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Psychiatry Gjerde, Priyanthi B. Steen, Synne W. Vedal, Trude S. J. Steen, Nils Eiel Reponen, Elina J. Andreassen, Ole A. Steen, Vidar M. Melle, Ingrid Lifetime Cannabis Use Is Not Associated With Negative Beliefs About Medication in Patients With First Treatment Psychosis |
title | Lifetime Cannabis Use Is Not Associated With Negative Beliefs About Medication in Patients With First Treatment Psychosis |
title_full | Lifetime Cannabis Use Is Not Associated With Negative Beliefs About Medication in Patients With First Treatment Psychosis |
title_fullStr | Lifetime Cannabis Use Is Not Associated With Negative Beliefs About Medication in Patients With First Treatment Psychosis |
title_full_unstemmed | Lifetime Cannabis Use Is Not Associated With Negative Beliefs About Medication in Patients With First Treatment Psychosis |
title_short | Lifetime Cannabis Use Is Not Associated With Negative Beliefs About Medication in Patients With First Treatment Psychosis |
title_sort | lifetime cannabis use is not associated with negative beliefs about medication in patients with first treatment psychosis |
topic | Psychiatry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9001842/ https://www.ncbi.nlm.nih.gov/pubmed/35422717 http://dx.doi.org/10.3389/fpsyt.2022.824051 |
work_keys_str_mv | AT gjerdepriyanthib lifetimecannabisuseisnotassociatedwithnegativebeliefsaboutmedicationinpatientswithfirsttreatmentpsychosis AT steensynnew lifetimecannabisuseisnotassociatedwithnegativebeliefsaboutmedicationinpatientswithfirsttreatmentpsychosis AT vedaltrudesj lifetimecannabisuseisnotassociatedwithnegativebeliefsaboutmedicationinpatientswithfirsttreatmentpsychosis AT steennilseiel lifetimecannabisuseisnotassociatedwithnegativebeliefsaboutmedicationinpatientswithfirsttreatmentpsychosis AT reponenelinaj lifetimecannabisuseisnotassociatedwithnegativebeliefsaboutmedicationinpatientswithfirsttreatmentpsychosis AT andreassenolea lifetimecannabisuseisnotassociatedwithnegativebeliefsaboutmedicationinpatientswithfirsttreatmentpsychosis AT steenvidarm lifetimecannabisuseisnotassociatedwithnegativebeliefsaboutmedicationinpatientswithfirsttreatmentpsychosis AT melleingrid lifetimecannabisuseisnotassociatedwithnegativebeliefsaboutmedicationinpatientswithfirsttreatmentpsychosis |